NCT06090825

Brief Summary

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 3, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 19, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

October 19, 2023

Status Verified

October 1, 2023

Enrollment Period

1 year

First QC Date

October 3, 2023

Last Update Submit

October 17, 2023

Conditions

Keywords

follow uppalliative carepancreatic cancer

Outcome Measures

Primary Outcomes (1)

  • Descriptions and scores of real status of hospice care in different hospitals

    The primary outcome is objective standards and subjective scores of current status of palliative care to qutify the development of palliative care of different hospitals. The score is evaluated by a follow-up questionnaire. The maximum and minimum score is 10 and 0, respectively.

    1 month

Study Arms (1)

Pancreatic cancer patients

Other: Observational study

Interventions

Observational study

Pancreatic cancer patients

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The doctors of the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland

You may qualify if:

  • Doctors from the General Surgery Department in Chinese public tertiary teaching hospitals and public primary care units
  • Approval to participate
  • Participants with a valid and complete questionnaire evaluated by 2 experienced surgeons

You may not qualify if:

  • Refusal to participate
  • Participants with an invalid or incomplete questionnaire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Qiaofei Liu

    Department of General Surgery, Peking Union Medical College Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department director assistant, clinical chief professor

Study Record Dates

First Submitted

October 3, 2023

First Posted

October 19, 2023

Study Start

September 1, 2023

Primary Completion

September 1, 2024

Study Completion

September 1, 2025

Last Updated

October 19, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations